Literature DB >> 8968609

Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution.

B S Chang1, R M Beauvais, T Arakawa, L O Narhi, A Dong, D I Aparisio, J F Carpenter.   

Abstract

The degradation products of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) formed during storage at 30 degrees C in aqueous solution were characterized. Cationic exchange chromatography of the stored sample showed two major, new peaks eluting before (P1) and after (L2) the native protein, which were interconvertible. Size-exclusion chromatography and electrophoresis documented that both the P1 and L2 fractions were irreversible dimers, formed by noncovalent interactions. A competition assay with interleukin-1 indicated that on a per monomer basis the P1 and L2 dimers retained about two-thirds of the activity of the native monomer. Infrared and far-UV circular dichroism spectroscopies showed that only minor alterations in secondary structure arose upon the formation of the P1 dimer. However, alteration in the near-UV circular dichroism spectrum suggested the presence of disulfide bonds in the P1 dimer, which are absent in the native protein. Mass spectroscopy and tryptic mapping, before and after carboxymethylation, demonstrated that the P1 dimer contained an intramolecular disulfide bond between Cys-66 and Cys-69. Although conversion of native protein to the P1 dimer was irreversible in buffer alone, the native monomer could be regained by denaturing the P1 dimer with guanidine hydrochloride and renaturing it by dialysis, suggesting that the intramolecular disulfide bond does not interfere with refolding. Analysis of the time course of P1 formation during storage at 30 degrees C indicated that the process followed first-order, and not second-order, kinetics, suggesting that the rate-limiting step was not dimerization. It is proposed that a conformational change in the monomer is the rate-limiting step in the formation of the P1 dimer degradation product. Sucrose stabilized the native monomer against this process. This result can be explained by the general stabilization mechanism for this additive, which is due to its preferential exclusion from the protein surface.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968609      PMCID: PMC1233827          DOI: 10.1016/S0006-3495(96)79534-6

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  33 in total

1.  Combining experimental information from crystal and solution studies: joint X-ray and NMR refinement.

Authors:  B Shaanan; A M Gronenborn; G H Cohen; G L Gilliland; B Veerapandian; D R Davies; G M Clore
Journal:  Science       Date:  1992-08-14       Impact factor: 47.728

Review 2.  Infrared methods for study of hemoglobin reactions and structures.

Authors:  A Dong; W S Caughey
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

3.  Stabilization of basic fibroblast growth factor with dextran sulfate.

Authors:  T Kajio; K Kawahara; K Kato
Journal:  FEBS Lett       Date:  1992-07-20       Impact factor: 4.124

4.  Study of the "molten globule" intermediate state in protein folding by a hydrophobic fluorescent probe.

Authors:  G V Semisotnov; N A Rodionova; O I Razgulyaev; V N Uversky; A F Gripas'; R I Gilmanshin
Journal:  Biopolymers       Date:  1991-01       Impact factor: 2.505

5.  Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 beta.

Authors:  J D Zhang; L S Cousens; P J Barr; S R Sprang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  Formulation design of acidic fibroblast growth factor.

Authors:  P K Tsai; D B Volkin; J M Dabora; K C Thompson; M W Bruner; J O Gress; B Matuszewska; M Keogan; J V Bondi; C R Middaugh
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

7.  X-ray structure of interleukin-1 receptor antagonist at 2.0-A resolution.

Authors:  G P Vigers; P Caffes; R J Evans; R C Thompson; S P Eisenberg; B J Brandhuber
Journal:  J Biol Chem       Date:  1994-04-29       Impact factor: 5.157

8.  Crystal structure of basic fibroblast growth factor at 1.6 A resolution.

Authors:  H Ago; Y Kitagawa; A Fujishima; Y Matsuura; Y Katsube
Journal:  J Biochem       Date:  1991-09       Impact factor: 3.387

9.  An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT.

Authors:  N W Roehm; G H Rodgers; S M Hatfield; A L Glasebrook
Journal:  J Immunol Methods       Date:  1991-09-13       Impact factor: 2.303

10.  Physical stabilization of acidic fibroblast growth factor by polyanions.

Authors:  D B Volkin; P K Tsai; J M Dabora; J O Gress; C J Burke; R J Linhardt; C R Middaugh
Journal:  Arch Biochem Biophys       Date:  1993-01       Impact factor: 4.013

View more
  10 in total

1.  Correlation of rFVIII inactivation with aggregation in solution.

Authors:  Wei Wang; Drew N Kelner
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

2.  Conformational change in the C-terminal domain is responsible for the initiation of creatine kinase thermal aggregation.

Authors:  Hua-Wei He; Jun Zhang; Hai-Meng Zhou; Yong-Bin Yan
Journal:  Biophys J       Date:  2005-07-08       Impact factor: 4.033

3.  Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state.

Authors:  B S Kendrick; B S Chang; T Arakawa; B Peterson; T W Randolph; M C Manning; J F Carpenter
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

4.  High-pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: thermodynamics, kinetics, and application to accelerated formulation studies.

Authors:  Matthew B Seefeldt; Yong-Sung Kim; Kevin P Tolley; Jim Seely; John F Carpenter; Theodore W Randolph
Journal:  Protein Sci       Date:  2005-08-04       Impact factor: 6.725

5.  Particle Formation and Aggregation of a Therapeutic Protein in Nanobubble Suspensions.

Authors:  Jared R Snell; Chen Zhou; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2016-07-31       Impact factor: 3.534

6.  A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma.

Authors:  B S Kendrick; J F Carpenter; J L Cleland; T W Randolph
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

7.  The cataract-associated R14C mutant of human gamma D-crystallin shows a variety of intermolecular disulfide cross-links: a Raman spectroscopic study.

Authors:  Ajay Pande; Darnelle Gillot; Jayanti Pande
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

8.  Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.

Authors:  Bei Chen; Raquel Bautista; Kwok Yu; Gerardo A Zapata; Michael G Mulkerrin; Steven M Chamow
Journal:  Pharm Res       Date:  2003-12       Impact factor: 4.200

9.  Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [¹⁸F]-IL1RA and PET imaging in rats.

Authors:  C Cawthorne; C Prenant; A Smigova; P Julyan; R Maroy; K Herholz; N Rothwell; H Boutin
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

10.  Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation.

Authors:  E Suzanne Cohen; Ian C Scott; Jayesh B Majithiya; Laura Rapley; Benjamin P Kemp; Elizabeth England; D Gareth Rees; Catherine L Overed-Sayer; Joanne Woods; Nicholas J Bond; Christel Séguy Veyssier; Kevin J Embrey; Dorothy A Sims; Michael R Snaith; Katherine A Vousden; Martin D Strain; Denice T Y Chan; Sara Carmen; Catherine E Huntington; Liz Flavell; Jianqing Xu; Bojana Popovic; Christopher E Brightling; Tristan J Vaughan; Robin Butler; David C Lowe; Daniel R Higazi; Dominic J Corkill; Richard D May; Matthew A Sleeman; Tomas Mustelin
Journal:  Nat Commun       Date:  2015-09-14       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.